Latest news with #NonclinicalStage
Globe and Mail
21 hours ago
- Business
- Globe and Mail
Endometrial Cancer Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Endometrial Cancer Pipeline Insight, 2025,' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometrial Cancer therapeutics assessment by product type, stage, Endometrial Cancer route of administration, and Endometrial Cancer molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Endometrial Cancer Treatment Landscape @ Endometrial Cancer Pipeline Outlook Key Takeaways from the Endometrial Cancer Pipeline Report In August 2025, Iovance Biotherapeutics, Inc. announced a study will enroll participants with advanced endometrial cancer who previously received treatment with platinum-based chemotherapy and an anti-programmed cell death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) agent in a recurrent or advanced setting, either sequentially or in combination. In August 2025, Merck Sharp & Dohme LLC conducted a clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy. In August 2025, Sichuan Baili Pharmaceutical Co., Ltd. organized a phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies. DelveInsight's Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Endometrial Cancer treatment. The leading Endometrial Cancer Companies such as Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others. Promising Endometrial Cancer Pipeline Therapies such as Ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others. Discover groundbreaking developments in Endometrial Cancer therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Endometrial Cancer Clinical Trials Assessment Endometrial Cancer Emerging Drugs Profile Selinexor: Karyopharm Therapeutics Selinexor (XPOVIO) is a first-in-class, oral exportin 1 (XPO1) inhibitor. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. The drug is being explored as a maintenance therapy for patients with advanced or recurrent endometrial cancer, particularly those with TP53 wild-type tumors. This approach is based on findings from the Phase III SIENDO study, which has shown promising results in improving progression-free survival (PFS) for this specific patient population. Currently it is being investigated in Phase III stage of development for the treatment of patients with Endometrial Cancer. Abemaciclib: Eli Lilly and Company Abemaciclib, developed by Eli Lilly, is showing promising clinical activity in combination with hormonal therapies for recurrent estrogen receptor (ER)-positive endometrioid endometrial cancer (EEC). In a phase 2 trial, abemaciclib plus hormonal therapy achieved a clinical benefit rate of 67% in EEC patients, with partial and complete responses observed and a median progression-free survival (PFS) around 6.1 months. Another study combining abemaciclib with letrozole demonstrated a 30% objective response rate and a median PFS of 9.1 months, with durable tumor shrinkage or stabilization in 75% of patients. Adding metformin to this combination further improved outcomes, inducing deeper and more durable responses by targeting multiple cancer pathways including estrogen receptor, CDK4/6, and PI3K. These findings support abemaciclib plus hormonal therapy as a promising treatment approach for recurrent ER-positive endometrial cancer, with ongoing trials confirming safety and efficacy. NP137: NETRIS Pharma NP137 is a humanized monoclonal antibody (IgG1) targeting netrin-1, a protein overexpressed in a large proportion of human cancers and associated with disease severity and resistance to therapy. By blocking netrin-1, NP137 is designed to restore apoptosis and reverse epithelial-to-mesenchymal transition (EMT), addressing critical mechanisms of resistance that limit the effectiveness of immune checkpoint inhibitors. Preclinical and early clinical studies have shown that NP137 has anti-cancer effects both as a monotherapy and in combination with chemotherapy or immunotherapy, with a favorable safety profile. According to the company's pipeline the drug is in the Phase II stage of development for the treatment of patients with Endometrial Cancer. CT-0508: Carisma Therapeutics CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). It is being evaluated in a landmark Phase I multi-center clinical trial that focuses on patients with recurrent or metastatic HER2-overexpressing solid tumors whose cancers are not eligible for treatment with currently available HER2-targeted therapies or who do not respond to treatment. The trial is enrolling participants who have tumors of any anatomical origin, but with the commonality of overexpressing the HER2 receptor on the cell surface, which is the target for our CAR-M. The Phase 1 clinical trial is first-of-its-kind, marking the first time that genetically engineered macrophages are being studied in humans. The trial continues to enroll patients at seven clinical sites in the U.S., including (i) the University of Pennsylvania Abramson Cancer Center, (ii) the University of North Carolina Lineberger Comprehensive Cancer Center, (iii) the City of Hope National Medical Center, (iv) the MD Anderson Cancer Center, (v) the Sarah Cannon Cancer Research Institute, (vi) Oregon Health & Science University and (vii) Fred Hutchinson Cancer Center. The Endometrial Cancer Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Endometrial Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometrial Cancer Treatment. Endometrial Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Endometrial Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometrial Cancer market Stay informed about the Endometrial Cancer pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Endometrial Cancer Unmet Needs Endometrial Cancer Companies Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others. Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Intramuscular Endometrial Cancer Products have been categorized under various Molecule types such as Small molecules Natural metabolites Monoclonal antibodies Transform your understanding of the Endometrial Cancer Pipeline! See the latest progress in drug development and clinical research @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Endometrial Cancer Pipeline Report Coverage- Global Endometrial Cancer Companies- Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others. Endometrial Cancer Pipeline Therapies- Ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others. Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Oncology Research–Access the Full Endometrial Cancer Pipeline Analysis Today! @ Endometrial Cancer Drugs and Companies Table of Contents Introduction Executive Summary Endometrial Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Endometrial Cancer – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Selinexor: Karyopharm Therapeutics Mid Stage Products (Phase II) Abemaciclib: Eli Lilly and Company Early Stage Products (Phase I/II) CT-0508: Carisma Therapeutics Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Endometrial Cancer Key Companies Endometrial Cancer Key Products Endometrial Cancer - Unmet Needs Endometrial Cancer - Market Drivers and Barriers Endometrial Cancer - Future Perspectives and Conclusion Endometrial Cancer Analyst Views Endometrial Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
a day ago
- Business
- Globe and Mail
Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Metastatic Castration-Resistant Prostate Cancer Pipeline Insights 2025' report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Castration-Resistant Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Metastatic Castration-Resistant Prostate Cancer Pipeline Report to explore emerging therapies, key Metastatic Castration-Resistant Prostate Cancer Companies, and future Metastatic Castration-Resistant Prostate Cancer treatment landscapes @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report In August 2025, Novartis Pharmaceuticals announced a Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated. announced a Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated. In August 2025, Pfizer announced a study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. announced a study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. In August 2025, Amgen conducted a study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]). conducted a study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]). In August 2025, Merck Sharp & Dohme LLC announced a study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2. Outcome measures will be assessed individually for each cohort. announced a study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2. Outcome measures will be assessed individually for each cohort. In August 2025, AstraZeneca organized a study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations. organized a study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations. DelveInsight's Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment. The leading Metastatic Castration-Resistant Prostate Cancer Companies such as Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others. and others. Promising Metastatic Castration-Resistant Prostate Cancer Therapies such as JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others. Discover how the Metastatic Castration-Resistant Prostate Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials and Studies Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile SRF617: Surface Oncology SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA. Rucaparib: Clovis Oncology Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. HP518: Hinova Pharmaceuticals HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR. The Metastatic Castration-Resistant Prostate Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Castration-Resistant Prostate Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Castration-Resistant Prostate Cancer Treatment. Metastatic Castration-Resistant Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Metastatic Castration-Resistant Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Castration-Resistant Prostate Cancer market. Get a detailed analysis of the latest innovations in the Metastatic Castration-Resistant Prostate Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Metastatic Castration-Resistant Prostate Cancer Unmet Needs Metastatic Castration-Resistant Prostate Cancer Companies Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others. Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Oral Intravenous Subcutaneous Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as Small molecule Cell Therapy Peptides Polymer Small molecule Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Metastatic Castration-Resistant Prostate Cancer Therapies and key Cervical Cancer Developments @ Metastatic Castration-Resistant Prostate Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report Coverage- Global Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen , and others. , and others. Metastatic Castration-Resistant Prostate Cancer Therapies- JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others. and others. Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Metastatic Castration-Resistant Prostate Cancer drug development? Find out in DelveInsight's exclusive Metastatic Castration-Resistant Prostate Cancer Pipeline Report—access it now! @ Metastatic Castration-Resistant Prostate Cancer Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Metastatic Castration Resistant Prostate Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Metastatic Castration Resistant Prostate Cancer– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Rucaparib: Clovis Oncology Drug profiles in the detailed report….. Mid Stage Products (Phase II) Surface Oncology: SRF 617 Drug profiles in the detailed report….. Early Stage Products (Phase I/II) REGN 4336: Regeneron Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) HP 518: Hinova Pharmaceuticals Drug profiles in the detailed report….. Inactive Products Metastatic Castration Resistant Prostate cancer Key Companies Metastatic Castration Resistant Prostate cancer Key Products Metastatic Castration Resistant Prostate cancer- Unmet Needs Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion Metastatic Castration Resistant Prostate cancer Analyst Views Metastatic Castration Resistant Prostate cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email Phone: 09650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape
